Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use
…
This year’s annual 340B recertification period for U.S. Centers for Disease Prevention and Control grantees—Title X family planning, sexually transmitted disease, and tuberculosis clinics—will be May 8 through June 5, the U.S. Health Resources and Services Administration said Tuesday.
Recertification
…
Pennsylvania health centers are upset about what they say was the state Medicaid office’s disclosure without warning last week that, starting July 1, it wants drug claims billed to Medicaid managed care organizations to include a modifier showing if the
…
The federal government yesterday decided not to ask all 14 judges on the U.S. Third Circuit Court of Appeals in Philadelphia to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when
…
Drug manufacturer Eli Lilly asked a 340B covered entity last week to promptly repay it for “duplicate 340B/Medicaid discounts” and evaluate all Lilly prescriptions that it or its contract pharmacies dispensed for the last three years.
Consultants and attorneys with
…
The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing to offer
…
Health care providers in Mississippi eligible to participate in the 340B program may do so immediately, rather than having to wait for the next normal quarterly registration period July 1-15, federal health officials said yesterday.
Strong tornadoes struck the state
…
Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis.
The U.S. Health Resources and Services Administration posted Dermavant’s notice to 340B covered
…
The second quarterly period this year for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin Saturday, April 1, and is expected to end on Monday, April 17.
Normally, a quarterly 340B registration period runs from
…
The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, a list that includes AbbVie’s blockbuster arthritis drug Humira, which generated $5.6 billion in global
…
×
*Sign up for news summaries and alerts from 340B Report